ClinicalTrials.gg
CompletedNCT06624228Updated Sep 2, 2026

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis

A Phase 3 interventional study of Bimekizumab and Risankizumab in Psoriatic Arthritis, sponsored by UCB Biopharma SRL. Completed at 127 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
553
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing bimekizumab in Arthritis, Psoriatic — 2 open to participants now, 3 under way, 1 of them phase 3. bimekizumab · Arthritis, Psoriatic.

Enrollment
4th of 14
553 · median 210
Started
2024
with 1 other
Phase 3
8 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
10 of 14
UCB Biopharma SRL

Among the 14 studies testing bimekizumab in Arthritis, Psoriatic, this one is the 4th largest by enrollment, is one of 2 that started in 2024, is one of 8 in phase 3, and was the 12th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

2 of the 14 studies testing bimekizumab in Arthritis, Psoriatic are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About bimekizumab

bimekizumab: first FDA approval 2023 (BIMZELX), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing bimekizumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of the study is to compare the efficacy of bimekizumab versus risankizumab after 16 weeks of treatment in study participants with active psoriatic arthritis (PsA).

03

Conditions studied

  • Psoriatic Arthritis

Keywords

  • bimekizumab
  • risankizumab
  • arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Study participants must have a documented diagnosis of adult-onset PsA classified by and that meets the CASPAR classification criteria for at least 6 months prior to Screening with active PsA (despite previous csDMARD or apremilast therapy) and must have at Baseline tender joint count (TJC) ≥3 out of 68 joints and swollen joint count (SJC) ≥3 out of 66 joints (dactylitis of a digit counts as 1 joint each).
  • Study participant must have at least 1 active psoriatic lesion(s) and/or a documented history of chronic plaque-type psoriasis (PSO).
  • Study participants may currently be on conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy and must have previously been treated with at least 1 csDMARD (methotrexate (MTX), leflunomide (LEF), sulfasalazine (SSZ)). Study participants must have had an inadequate response to therapy or discontinued due to intolerance. (Inadequate response is determined by the Investigator and is defined as not achieving the minimal response after 12 weeks of therapy.)
  • Study participants can either be biological disease-modifying antirheumatic drug (bDMARD)-naïve or have received not more than 1 prior tumor necrosis factor alpha (TNFα) inhibitor. Study participants who have been on a TNFα inhibitor previously must not have discontinued the TNFα inhibitor due to financial or health insurance reasons and must have either:
  • experienced an inadequate response to previous treatment given at an approved dose for at least 3 months, or
  • been intolerant to administration (eg, had a side-effect/adverse event (AE) that led to discontinuation).

Exclusion criteria

Exclusion Criteria:

  • Study participant has any medical or psychiatric condition that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study.
  • Female participants who are breastfeeding, pregnant, or plan to become pregnant during the study.
  • Participant has an active infection or a history of recent serious infections.
  • Participant has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection.
  • Study participant has a diagnosis of inflammatory conditions other than PSO or PsA including, but not limited to, rheumatoid arthritis, sarcoidosis, systemic lupus erythematosus, reactive arthritis, and axial spondyloarthritis.
  • Study participants with a history of anterior uveitis are allowed if they have no active symptoms at Screening or Baseline. Study participants with a diagnosis of Crohn's disease or ulcerative colitis are allowed if they have no active symptomatic disease at Screening or Baseline.
  • Study participants with fibromyalgia or osteoarthritis symptoms that in the Investigator's opinion would have potential to interfere with efficacy assessments.
  • Participant has any active or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer.
  • Participant has a history of chronic alcohol or drug abuse within 6 months prior to Screening.
  • Study participants taking psoriatic arthritis (PsA) medications other than MTX, SSZ, apremilast, hydroxychloroquine (HCQ), LEF, nonsteroidal anti-inflammatory drug (NSAIDs)/ cyclooxygenase-2 (COX-2) inhibitors, oral , and analgesics as outlined in the Inclusion criteria.
  • Study participant is taking or has taken prohibited PsA or PSO medications without meeting the mandatory relative to the Baseline Visit or is taking or has taken weight management medications without meeting the mandatory dose stability period/washout period relative to the Baseline Visit.
  • Study participant is taking or has taken janus kinase (JAK) inhibitor.
  • Study participant is taking or has taken bDMARDs, including bimekizumab or risankizumab, with the exception of having received 1 prior TNFα inhibitor.
  • Study participant previously participated in another study of a medical device under investigation within the 4 weeks prior to the Screening Visit or is currently participating in another study of a medical device under investigation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
553 participants (actual)

Study arms

  • Experimental
    Bimekizumab

    Study participants will receive assigned bimekizumab dosage regimen and placebo to maintain the blinding during treatment period.

    Drug: Bimekizumab · Drug: Placebo

  • Active comparator
    Risankizumab

    Study participants will receive assigned risankizumab dosage regimen and placebo to maintain the blinding during treatment period.

    Drug: Risankizumab · Drug: Placebo

Interventions

  • Study participants will receive bimekizumab at pre-specified time points.

  • Study participants will receive risankizumab at pre-specified time points.

  • DrugPlacebo

    Study participants will receive placebo at pre-specified time points.

06

What researchers measure

Primary outcomes

  1. American College of Rheumatology 50 (ACR50) at Week 16

    The ACR50 response rate is based on a 50% or greater improvement of arthritis relative to Baseline. * TJC and SJC: 2-point scale (0=absent;1=present) • Patient's Global Assessment of Psoriatic Arthritis (PGA-PsA): 100 VAS (0=very good, no symptoms;100=very poor, severe symptoms) * Physician's Global Assessment of Psoriatic Arthritis (PhGA-PsA): 100 VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • Patient's Assessment of Arthritis Pain (PtAAP): 100 VAS (0=no pain;100=most severe pain). * Health Assessment Questionnaire Disability Index score (HAQ-DI) assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. * High sensitivity C-reactive protein (hs-CRP) in mg/L

    Time frame: Week 16

Secondary outcomes

  1. Minimal Disease Activity (MDA) at Week 16

    A study participant is considered as having MDA if 5 or more of the following 7 criteria are fulfilled: * Tender joint count ≤1 * Swollen joint count ≤1 * PASI ≤1 or BSA ≤3 * PtAAP VAS ≤15 * PGA-PsA VAS ≤20 * HAQ-DI ≤0.5 * Tender enthesial points ≤1

    Time frame: Week 16

  2. Percentage of participants reaching the composite endpoint composed of ACR50 and Psoriasis Area and Severity Index 100% (PASI100) response at Week 16 in the subgroup of study participants with PSO involving at least 3% body surface area (BSA) at Baseline

    The ACR50 response rate is based on a 50% or greater improvement of arthritis relative to Baseline. The PASI100 response is based on at least 100% improvement in the PASI score. Body divided into 4 areas: head, upper extremities, trunk and lower extremities. Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked). Determining the percentage of skin covered with PSO for each of body areas and converting to a 0 to 6 scale. Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section. The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.

    Time frame: Week 16

  3. American College of Rheumatology 50 (ACR50) at Week 4

    The ACR50 response rate is based on a 50% or greater improvement of arthritis relative to Baseline. * TJC and SJC: 2-point scale (0=absent;1=present) • Patient's Global Assessment of Psoriatic Arthritis (PGA-PsA): 100 VAS (0=very good, no symptoms;100=very poor, severe symptoms) * Physician's Global Assessment of Psoriatic Arthritis (PhGA-PsA): 100 VAS (0=very good, asymptomatic, no limitation of normal activities;100=very poor, very severe symptoms which were intolerable, inability to carry out all normal activities). • Patient's Assessment of Arthritis Pain (PtAAP): 100 VAS (0=no pain;100=most severe pain). * Health Assessment Questionnaire Disability Index score (HAQ-DI) assessed degree of difficulty experienced in 8 domains of daily living activities (20 questions), total score (0-3) computed from item scores, with lower scores meaning less disability. * High sensitivity C-reactive protein (hs-CRP) in mg/L

    Time frame: Week 4

  4. Incidence of Participants With Treatment-emergent adverse events (TEAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP.

    Time frame: From Baseline (Day 1) to End of Safety Follow-Up (up to 37 weeks)

  5. Incidence of Participants With Treatment-emergent serious AEs

    A Serious Adverse Event (SAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalization or prolongation of existing hospitalization Is a congenital anomaly or birth defect * Results in permanent or significant disability/incapacity * Other important medical events which based on medical or scientific judgement may jeopardize the patients, or may require medical or surgical intervention to prevent any of the above

    Time frame: From Baseline (Day 1) to End of Safety Follow-Up (up to 37 weeks)

  6. Incidence of Participants With TEAEs leading to withdrawal from investigational medicinal product (IMP)

    An AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP.

    Time frame: From Baseline (Day 1) to End of Safety Follow-Up (up to 37 weeks)

07

Study locations

127 sites
  • Pa0016 50662
    Gilbert, Arizona 85297, United States
  • Pa0016 50062
    Glendale, Arizona 85306, United States
  • Pa0016 50058
    Phoenix, Arizona 85032, United States
  • Pa0016 50131
    Sun City, Arizona 85351, United States
  • Pa0016 50654
    Covina, California 91722, United States
  • Pa0016 50663
    San Diego, California 92128, United States
  • Pa0016 50672
    Santa Monica, California 90404, United States
  • Pa0016 50630
    Clearwater, Florida 33765, United States
  • Pa0016 50679
    Cutler Bay, Florida 33189, United States
  • Pa0016 50685
    Fort Lauderdale, Florida 33309, United States
  • Pa0016 50059
    Ormond Beach, Florida 32174, United States
  • Pa0016 50324
    Plantation, Florida 33324, United States
  • Pa0016 50678
    Zephyrhills, Florida 33542, United States
  • Pa0016 50651
    Skokie, Illinois 60076, United States
  • Pa0016 50650
    Willowbrook, Illinois 60527, United States
  • Pa0016 50686
    Hagerstown, Maryland 21740, United States
  • Pa0016 50665
    Lansing, Michigan 48910, United States
  • Pa0016 50551
    Saint Clair Shores, Michigan 48081, United States
  • Pa0016 50689
    Eagan, Minnesota 55123, United States
  • Pa0016 50682
    Kansas City, Missouri 64111, United States
  • Pa0016 50016
    St Louis, Missouri 63141, United States
  • Pa0016 50653
    Albuquerque, New Mexico 87102, United States
  • Pa0016 50666
    Brooklyn, New York 11201, United States
  • Pa0016 50664
    Middletown, Ohio 45044, United States
  • Pa0016 50680
    Vandalia, Ohio 45377, United States
  • Pa0016 50652
    Duncansville, Pennsylvania 16635, United States
  • Pa0016 50006
    Wyomissing, Pennsylvania 19610, United States
  • Pa0016 50001
    Jackson, Tennessee 38305, United States
  • Pa0016 50673
    Fort Worth, Texas 76109, United States
  • Pa0016 50048
    Katy, Texas 77449, United States
  • Pa0016 50657
    Lubbock, Texas 79424, United States
  • Pa0016 50655
    Tomball, Texas 77375, United States
  • Pa0016 50061
    Spokane Valley, Washington 99216, United States
  • Pa0016 50674
    Glendale, Wisconsin 53217, United States
  • Pa0016 30002
    Clayton, Australia
  • Pa0016 30034
    Footscray, Australia
  • Pa0016 30033
    Heidelberg, Australia
  • Pa0016 30003
    Maroochydore, Australia
  • Pa0016 30032
    Parramatta, Australia
  • Pa0016 30009
    Westmead, Australia
  • Pa0016 40313
    Pleven, Bulgaria
  • Pa0016 40006
    Plovdiv, Bulgaria
  • Pa0016 40813
    Plovdiv, Bulgaria
  • Pa0016 40818
    Plovdiv, Bulgaria
  • Pa0016 40820
    Plovdiv, Bulgaria
  • Pa0016 40656
    Rousse, Bulgaria
  • Pa0016 40823
    Rousse, Bulgaria
  • Pa0016 40314
    Sofia, Bulgaria
  • Pa0016 40380
    Sofia, Bulgaria
  • Pa0016 40811
    Sofia, Bulgaria
  • Pa0016 40819
    Sofia, Bulgaria
  • Pa0016 50041
    Québec, Canada
  • Pa0016 50044
    Trois-Rivières, Canada
  • Pa0016 40065
    Brno, Czechia
  • Pa0016 40062
    Moravska Ostrava A Privoz, Czechia
  • Pa0016 40802
    Ostrava, Czechia
  • Pa0016 40066
    Prague, Czechia
  • Pa0016 40801
    Prague, Czechia
  • Pa0016 40010
    Uherské Hradiště, Czechia
  • Pa0016 40012
    Zlín, Czechia
  • Pa0016 40073
    Bad Nauheim, Germany
  • Pa0016 40025
    Berlin, Germany
  • Pa0016 40138
    Bonn, Germany
  • Pa0016 40808
    Cologne, Germany
  • Pa0016 40072
    Freiburg im Breisgau, Germany
  • Pa0016 40029
    Hamburg, Germany
  • Pa0016 40810
    Herne, Germany
  • Pa0016 40724
    München, Germany
  • Pa0016 40800
    Ratingen, Germany
  • Pa0016 40081
    Budapest, Hungary
  • Pa0016 40804
    Budapest, Hungary
  • Pa0016 40809
    Hódmezővásárhely, Hungary
  • Pa0016 40031
    Szeged, Hungary
  • Pa0016 20035
    Bunkyō City, Japan
  • Pa0016 20043
    Itabashi-ku, Japan
  • Pa0016 20045
    Kita-gun, Japan
  • Pa0016 20049
    Kitakyushu, Japan
  • Pa0016 20069
    Meguro-ku, Japan
  • Pa0016 20336
    Mitaka-shi, Japan
  • Pa0016 20041
    Osaka, Japan
  • Pa0016 20046
    Osaka, Japan
  • Pa0016 20031
    Sapporo, Japan
  • Pa0016 40789
    Bialystok, Poland
  • Pa0016 40791
    Bialystok, Poland
  • Pa0016 40824
    Bialystok, Poland
  • Pa0016 40119
    Bydgoszcz, Poland
  • Pa0016 40798
    Bydgoszcz, Poland
  • Pa0016 40038
    Elblag, Poland
  • Pa0016 40795
    Katowice, Poland
  • Pa0016 40092
    Krakow, Poland
  • Pa0016 40490
    Krakow, Poland
  • Pa0016 40502
    Krakow, Poland
  • Pa0016 40792
    Krakow, Poland
  • Pa0016 40037
    Lublin, Poland
  • Pa0016 40483
    Nadarzyn, Poland
  • Pa0016 40091
    Nowa Sól, Poland
  • Pa0016 40796
    Olsztyn, Poland
  • Pa0016 40794
    Opole, Poland
  • Pa0016 40044
    Poznan, Poland
  • Pa0016 40090
    Poznan, Poland

Showing the first 100 of 127 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Feb 2026, 15 months.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 15 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 2, 2024
StartActual
Oct 21, 2024
Primary completionActual
Feb 6, 2026
CompletionActual
Jun 3, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06624228
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Oct 21, 2024
Primary completion
Feb 6, 2026
Completion
Jun 3, 2026
Last update
Sep 2, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimekizumab

Start the discussion